Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech’s Top-Line AVADO Data Strong With Avastin For Breast Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Though not registrational, study could bolster NDA package.

You may also be interested in...



Price, Not Safety, Most Likely To Limit Avastin Use In Breast Cancer – JPMorgan Physician Survey

Long-term revenue upside for drug in all indications could be as much as $6.5 billion by 2012, says JPMorgan analyst Geoffrey Meacham.

Price, Not Safety, Most Likely To Limit Avastin Use In Breast Cancer – JPMorgan Physician Survey

Long-term revenue upside for drug in all indications could be as much as $6.5 billion by 2012, says JPMorgan analyst Geoffrey Meacham.

Genentech Watchers Weigh Deeper Meaning Of Avastin’s Approval

FDA’s breast-cancer decision not a universal surprise, and there’s still risk in RIBBON-1.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel